|
US5476932A
(en)
*
|
1994-08-26 |
1995-12-19 |
Hoffmann-La Roche Inc. |
Process for producing N4-acyl-5'-deoxy-5-fluorocytidine derivatives
|
|
EP0882734B1
(en)
*
|
1997-06-02 |
2009-08-26 |
F. Hoffmann-La Roche Ag |
5'-Deoxy-cytidine derivatives
|
|
NZ330360A
(en)
*
|
1997-06-02 |
1999-03-29 |
Hoffmann La Roche |
5'-deoxy-cytidine derivatives, their manufacture and use as antitumoral agents
|
|
US6005098A
(en)
*
|
1998-02-06 |
1999-12-21 |
Hoffmann-La Roche Inc. |
5'deoxycytidine derivatives
|
|
IL141951A0
(en)
*
|
1998-09-25 |
2002-03-10 |
Warner Lambert Co |
Chemotherapy of cancer with acetyldinaline in combination with gemcitabine, capecitabine or cisplatin
|
|
US20080113025A1
(en)
*
|
1998-11-02 |
2008-05-15 |
Elan Pharma International Limited |
Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
|
|
US20070122481A1
(en)
*
|
1998-11-02 |
2007-05-31 |
Elan Corporation Plc |
Modified Release Compositions Comprising a Fluorocytidine Derivative for the Treatment of Cancer
|
|
CA2401191C
(en)
|
2000-02-28 |
2006-05-02 |
Aventis Pharma S.A. |
A composition comprising camptothecin and a pyrimidine derivative for the treatment of cancer
|
|
AU2001246863A1
(en)
*
|
2000-04-11 |
2001-10-23 |
Sayuri Yamada |
Curcumin compositions
|
|
KR100730768B1
(ko)
*
|
2000-08-09 |
2007-06-21 |
코오롱생명과학 주식회사 |
5'-데옥시-ｎ-알킬옥시카르보닐-5-플루오로사이토신-5'-카르복실산 및 그 유도체와 이들의 제조방법
|
|
KR100631754B1
(ko)
*
|
2000-08-09 |
2006-10-09 |
주식회사 코오롱 |
Ｎ-알킬옥시카르보닐-5-플루오로사이토신 유도체 및 그의제조방법
|
|
GB0113374D0
(en)
*
|
2001-06-04 |
2001-07-25 |
Jerram Clare |
Washing line umbrella
|
|
WO2003057217A1
(en)
*
|
2002-01-14 |
2003-07-17 |
Novartis Ag |
Combinations comprising epothilones and anti-metabolites
|
|
JP4625637B2
(ja)
|
2002-02-22 |
2011-02-02 |
シャイア エルエルシー |
活性物質送達系及び活性物質を保護し投与する方法
|
|
MXPA05003431A
(es)
*
|
2002-11-15 |
2005-07-05 |
Warner Lambert Co |
Quimioterapia de combinacion.
|
|
AU2003233586A1
(en)
*
|
2003-05-20 |
2005-01-21 |
Aronex Pharmaceuticals, Inc. |
Combination chemotherapy comprising capecitabine and a liposomal platinum complex
|
|
JP2007511499A
(ja)
*
|
2003-11-13 |
2007-05-10 |
ファーマ・マール・エス・アー・ウー |
コンビネーション
|
|
KR20080046752A
(ko)
*
|
2003-12-22 |
2008-05-27 |
에프. 호프만-라 로슈 아게 |
플루오로시티딘 유도체에 대한 방법
|
|
DK1848414T3
(da)
|
2005-02-03 |
2011-07-25 |
Gen Hospital Corp |
Fremgangsmåde til behandling af gefitinib-resistent cancer
|
|
AU2006228581A1
(en)
*
|
2005-04-01 |
2006-10-05 |
F. Hoffmann-La Roche Ag |
Method for administration of capecitabine
|
|
CN101242822B
(zh)
|
2005-07-18 |
2011-08-24 |
彼帕科学公司 |
治疗卵巢癌的药物
|
|
JP2009501734A
(ja)
|
2005-07-21 |
2009-01-22 |
ヌボ・リサーチ・インコーポレイテッド |
癌の治療方法
|
|
JP2009514870A
(ja)
|
2005-11-04 |
2009-04-09 |
ワイス |
ｍＴＯＲインヒビター、ハーセプチン、および／またはＨＫＩ−２７２の抗悪性腫瘍性組み合わせ
|
|
LT2426129T
(lt)
|
2005-12-13 |
2017-02-10 |
Incyte Holdings Corporation |
Heteroarilu pakeisti pirolo[2,3-b]piridinai ir pirolo[2,3-b]pirimidinai kaip janus kinazės inhibitoriai
|
|
US20100160442A1
(en)
*
|
2006-07-18 |
2010-06-24 |
Ossovskaya Valeria S |
Formulations for cancer treatment
|
|
US20080085310A1
(en)
*
|
2006-10-06 |
2008-04-10 |
Maria Oksana Bachynsky |
Capecitabine rapidly disintegrating tablets
|
|
CN100425617C
(zh)
*
|
2006-10-31 |
2008-10-15 |
浙江海正药业股份有限公司 |
一种含氟嘧啶类化合物烷氧羰酰化的方法
|
|
ITMI20070435A1
(it)
|
2007-03-05 |
2008-09-06 |
Innovate Biotechnology Srl |
2',3'-di-o-acil-5-fluoronucleosidi
|
|
KR20100015568A
(ko)
*
|
2007-04-20 |
2010-02-12 |
닥터 레디스 레보러터리즈 리미티드 |
카페시타빈의 제조 방법
|
|
WO2008145403A1
(en)
*
|
2007-06-01 |
2008-12-04 |
Synthon B.V. |
Processes related to making capecitabine
|
|
RS54878B1
(sr)
|
2007-06-13 |
2016-10-31 |
Incyte Holdings Corp |
Kristalne soli inhibitora janus kinaze (r)-3-(4-(7h-pirolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)-3-ciklopentilpropionitril
|
|
US7842675B2
(en)
*
|
2007-09-15 |
2010-11-30 |
Protia, Llc |
Deuterium-enriched capecitabine
|
|
WO2009042064A2
(en)
|
2007-09-21 |
2009-04-02 |
Nektar Therapeutics Al, Corporation |
Oligomer-nucleoside phosphate conjugates
|
|
US8022216B2
(en)
|
2007-10-17 |
2011-09-20 |
Wyeth Llc |
Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
|
|
KR101013312B1
(ko)
*
|
2007-11-19 |
2011-02-09 |
한미홀딩스 주식회사 |
카페시타빈의 제조방법 및 이에 사용되는 β-아노머가강화된 트리알킬카보네이트 화합물의 제조방법
|
|
AR064165A1
(es)
|
2007-12-06 |
2009-03-18 |
Richmond Sa Com Ind Y Financie |
Un procedimiento para la preparacion de capecitabina e intermediarios utilizables en dicho procedimiento
|
|
EP2225566A1
(en)
*
|
2008-01-03 |
2010-09-08 |
Plus Chemicals S.A. |
Process for the preparation of capecitabine
|
|
US20090311335A1
(en)
*
|
2008-06-12 |
2009-12-17 |
Scott Jenkins |
Combination of a triptan and an nsaid
|
|
KR101922096B1
(ko)
|
2008-06-17 |
2018-11-27 |
와이어쓰 엘엘씨 |
Ｈｋｉ-272 및 비노렐빈을 함유하는 항신생물성 조합물
|
|
DK2326329T3
(en)
|
2008-08-04 |
2017-02-20 |
Wyeth Llc |
Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
|
|
WO2010065586A2
(en)
*
|
2008-12-02 |
2010-06-10 |
Dr. Reddy's Laboratories Ltd. |
Preparation of capecitabine
|
|
EP2393472B1
(en)
*
|
2008-12-05 |
2019-06-05 |
NanoMed Holdings Pty Ltd |
Amphiphile prodrugs
|
|
HRP20230315T1
(hr)
|
2009-04-06 |
2023-05-12 |
Wyeth Llc |
Režim liječenja raka dojke korištenjem neratiniba
|
|
FR2945211A1
(fr)
|
2009-05-06 |
2010-11-12 |
Sanofi Aventis |
Combinaison antitumorale comprenant la cabazitaxel et la capecitabine
|
|
UA106078C2
(uk)
|
2009-05-22 |
2014-07-25 |
Інсайт Корпорейшн |
3-[4-(7H-ПІРОЛО[2,3-d]ПІРИМІДИН-4-ІЛ)-1H-ПІРАЗОЛ-1-ІЛ]ОКТАН- АБО ГЕПТАННІТРИЛ ЯК JAK-ІНГІБІТОРИ
|
|
JP2012533618A
(ja)
*
|
2009-07-23 |
2012-12-27 |
サイノファーム タイワン リミテッド |
フルオロシチジン誘導体の製造プロセス
|
|
WO2011067588A1
(en)
|
2009-12-04 |
2011-06-09 |
Generics [Uk] Limited |
Cyclic sulphinyl esters of cytidine
|
|
WO2011104540A1
(en)
*
|
2010-02-24 |
2011-09-01 |
Generics [Uk] Limited |
One step process for the preparation of capecitabine
|
|
MX364636B
(es)
|
2010-03-10 |
2019-05-03 |
Incyte Corp |
Derivados de piperidin-4-il azetidina como inhibidores de janus cinasa 1 (jak1).
|
|
HUE040107T2
(hu)
|
2010-03-12 |
2019-02-28 |
Genzyme Corp |
Kombinációs terápia mellrák kezelésére
|
|
SI2574168T1
(sl)
|
2010-05-21 |
2016-07-29 |
Incyte Holdings Corporation |
Topična formulacija zaviralca jak
|
|
CN102260309B
(zh)
*
|
2010-05-24 |
2014-10-22 |
重庆福安药业(集团)股份有限公司 |
一种高纯度卡培他滨的制备方法
|
|
SG190839A1
(en)
|
2010-11-19 |
2013-07-31 |
Incyte Corp |
Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
|
|
CN102558262A
(zh)
*
|
2010-12-23 |
2012-07-11 |
天津泰普药品科技发展有限公司 |
一种高纯度卡培他滨的制备方法
|
|
AU2012273164B2
(en)
|
2011-06-20 |
2015-05-28 |
Incyte Holdings Corporation |
Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
|
|
CN102266303A
(zh)
*
|
2011-07-07 |
2011-12-07 |
程雪翔 |
一种卡培他滨药用组合物及其制备方法
|
|
UA111854C2
(uk)
|
2011-09-07 |
2016-06-24 |
Інсайт Холдінгс Корпорейшн |
Способи і проміжні сполуки для отримання інгібіторів jak
|
|
CN102516338B
(zh)
*
|
2011-12-09 |
2014-04-02 |
海南锦瑞制药股份有限公司 |
一种卡培他滨化合物、其药物组合物及其制备方法
|
|
TWI560195B
(en)
*
|
2012-01-13 |
2016-12-01 |
Pharmaessentia Corp |
Novel synthesis of 5-deoxy-5'-fluorocytidine compounds
|
|
JP2015537030A
(ja)
|
2012-11-15 |
2015-12-24 |
インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ |
ルキソリチニブの徐放性投薬形態
|
|
KR102366356B1
(ko)
|
2013-03-06 |
2022-02-23 |
인사이트 홀딩스 코포레이션 |
Jak 저해제를 제조하기 위한 방법 및 중간생성물
|
|
EP3721873A1
(en)
|
2013-08-07 |
2020-10-14 |
Incyte Corporation |
Sustained release dosage forms for a jak1 inhibitor
|
|
EA201690421A1
(ru)
*
|
2013-08-20 |
2016-06-30 |
Инсайт Корпорейшн |
Положительный эффект в форме увеличения продолжительности жизни у больных с солидными опухолями с повышенными уровнями c-реактивного белка
|
|
EP2883959A1
(en)
|
2013-12-13 |
2015-06-17 |
Plasmia Biotech, S.L. |
Enzymatic production of cytosinic nucleoside analogues
|
|
CN103897006A
(zh)
*
|
2013-12-18 |
2014-07-02 |
吉林修正药业新药开发有限公司 |
一种卡培他滨异构体的制备方法
|
|
WO2015191576A1
(en)
|
2014-06-09 |
2015-12-17 |
Lipomedix Pharmaceuticals Ltd. |
Combination therapy comprising a liposomal prodrug of mitomycin c and radiotherapy
|
|
CN104530164A
(zh)
*
|
2014-12-31 |
2015-04-22 |
辰欣药业股份有限公司 |
一种卡培他滨的合成工艺
|
|
KR20160117060A
(ko)
|
2015-03-31 |
2016-10-10 |
이승주 |
유아용 탁자
|
|
CN105646625B
(zh)
*
|
2015-12-29 |
2019-06-11 |
江苏吴中医药集团有限公司 |
一种卡培他滨的制备方法
|
|
US11034667B2
(en)
|
2017-01-09 |
2021-06-15 |
Shuttle Pharmaceuticals, Inc. |
Selective histone deacetylase inhibitors for the treatment of human disease
|
|
US11584733B2
(en)
|
2017-01-09 |
2023-02-21 |
Shuttle Pharmaceuticals, Inc. |
Selective histone deacetylase inhibitors for the treatment of human disease
|
|
TR201702500A2
(tr)
*
|
2017-02-20 |
2017-07-21 |
Anadolu Ueniversitesi |
Serani̇b-2?ni̇n akci̇ğer kanseri̇ ve meme kanseri̇ni̇n tedavi̇si̇nde kullanimi
|
|
US10435429B2
(en)
|
2017-10-03 |
2019-10-08 |
Nucorion Pharmaceuticals, Inc. |
5-fluorouridine monophosphate cyclic triester compounds
|
|
TW201924683A
(zh)
|
2017-12-08 |
2019-07-01 |
美商英塞特公司 |
用於治療骨髓增生性贅瘤的低劑量組合療法
|
|
EP3737376B1
(en)
|
2018-01-09 |
2024-04-17 |
Shuttle Pharmaceuticals, Inc. |
Selective histone deacetylase inhibitors for the treatment of human diseases
|
|
AU2019207626B2
(en)
|
2018-01-10 |
2023-10-05 |
Nucorion Pharmaceuticals, Inc. |
Phosphor(n)amidatacetal and phosph(on)atalcetal compounds
|
|
US11427550B2
(en)
|
2018-01-19 |
2022-08-30 |
Nucorion Pharmaceuticals, Inc. |
5-fluorouracil compounds
|
|
WO2019143860A1
(en)
*
|
2018-01-19 |
2019-07-25 |
Nucorion Pharmaceuticals, Inc. |
5-fluorouracil compounds
|
|
AR114810A1
(es)
|
2018-01-30 |
2020-10-21 |
Incyte Corp |
Procesos e intermedios para elaborar un inhibidor de jak
|
|
CN113768934A
(zh)
|
2018-03-30 |
2021-12-10 |
因赛特公司 |
使用jak抑制剂治疗化脓性汗腺炎
|
|
AU2020207026A1
(en)
|
2019-01-11 |
2021-07-29 |
Lipomedix Pharmaceuticals Ltd. |
Liposome composition comprising liposomal prodrug of mitomycin C and method of manufacture
|
|
US12110311B2
(en)
|
2019-07-17 |
2024-10-08 |
Nucorion Pharmaceuticals, Inc. |
Cyclic deoxyribonucleotide compounds
|
|
CN115605492A
(zh)
|
2020-04-21 |
2023-01-13 |
配体制药股份有限公司（Us） |
核苷酸前药化合物
|
|
US11833155B2
(en)
|
2020-06-03 |
2023-12-05 |
Incyte Corporation |
Combination therapy for treatment of myeloproliferative neoplasms
|
|
WO2023177894A1
(en)
|
2022-03-18 |
2023-09-21 |
Ideaya Biosciences, Inc. |
Combination therapy comprising a mat2a inhibitor and an antimetabolite agent
|
|
EP4382093A1
(en)
|
2022-12-05 |
2024-06-12 |
a Fine House S.A. |
Oral suspensions comprising capecitabine
|